7/22/2013

OXiGENE's experimental ovarian cancer drug Zybrestat obtained orphan-drug designation from the European Medicines Agency. The drug, in combination with Roche Holding's Avastin, is in a midstage study for patients with advanced ovarian cancer. Data from the trial could be released next year.

Related Summaries